{
    "Trade/Device Name(s)": [
        "PlasmaCon N",
        "PlasmaCon L-1",
        "PlasmaCon L-2"
    ],
    "Submitter Information": "R2 Diagnostics, Inc.",
    "510(k) Number": "K062306",
    "Predicate Device Reference 510(k) Number(s)": [
        "K895262",
        "K895260",
        "K895261"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GIZ",
        "GGC"
    ],
    "Summary Letter Date": "March 16, 2007",
    "Summary Letter Received Date": "August 8, 2006",
    "Submission Date": "July 24, 2006",
    "Regulation Number(s)": [
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Multipurpose System For In Vitro Coagulation Studies"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Prothrombin Time (PT)",
        "Activated Partial Thromboplastin Time (aPTT)"
    ],
    "Specimen Type(s)": [
        "Plasma (citrated human plasma)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL3000+",
        "MLA1000c",
        "ACL Advance",
        "Dade BCS",
        "Stago STA"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for R2 Diagnostics PlasmaCon N, PlasmaCon L-1, and PlasmaCon L-2 lyophilized human plasma controls for PT and aPTT assay system performance verification.",
    "Indications for Use Summary": "Intended for use as normal, mid-level abnormal, and high-level abnormal lyophilized plasma controls with citrated plasma to monitor the performance of prothrombin time (PT) and activated partial thromboplastin time (aPTT) tests.",
    "fda_folder": "Hematology"
}